BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 13, 2020
Product Development

Next-generation sickle cell readouts at ASH: Data Byte

The move toward sickle cell disease therapies that address the pathology’s root causes is reflected in promising early-stage readouts at ASH, which include both disease event rates and changes in red blood cell biology. The...
BioCentury | Nov 7, 2020
Finance

Apollomics anchors investor base in Asia with $124M raise as it readies for its next phase of growth

Apollomics has shored up its Asian investor base with a $124 million series C round that provides the oncology company with flexibility to advance its pair of lead compounds while continuing to hunt for...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

Gilead’s second CAR T under Priority Review Gilead Sciences Inc. (NASDAQ:GILD) said FDA accepted and granted Priority Review to a BLA for KTE-X19 to treat adults with relapse or refractory mantle cell lymphoma. The anti-CD19...
BioCentury | Jan 7, 2020
Company News

Jan. 6 Company Quick Takes: China approvals for AZ, Sanofi and Gene+; plus Apollomics-GlycoMimetics, Pfizer-Merck KGaA and more

Trio of approvals from China’s NMPA China’s National Medical Products Administration approved NDAs for Lokelma sodium zirconium cyclosilicate from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat hyperkalemia and anti-PCSK9 mAb Praluent alirocumab from Sanofi (Euronext:SAN; NASDAQ:SNY)...
BioCentury | Nov 19, 2019
Clinical News

Vertex, CRISPR show early benefits with therapy, but longer term data are needed to show how it stacks up

...rolling BLA submission to FDA for Zynteglo this year. In sickle cell disease, FDA approved anti-P selectin...
BioCentury | Nov 16, 2019
Company News

Approval of first targeted sickle cell therapy heralds arrival of new agents

...by FDA, designed to cut the disease’s pathology at the root. The agency approved the anti-P selectin...
...Priority Review, and has Orphan Drug status. Elizabeth S. Eaton, Staff Writer crizanlizumab (SEG101, selg1) Novartis AG P selectin (SELP) (CD62P) Adakveo...
BioCentury | Nov 11, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

...candidates for approval, which it will evaluate based on different primary endpoints. Approval of the anti-P selectin...
...FDA and other health authorities, and link to crizanlizumab's MOA. "'Crizanlizumab acts by binding to P selectin...
...cell CLL lymphoma 11A HDAC - Histone deacetylase IL-1β - Interleukin-1 β SELP (CD62P) - P selectin Karen...
BioCentury | Nov 9, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

...candidates for approval, which it will evaluate based on different primary endpoints. Approval of the anti-P selectin...
...FDA and other health authorities, and link to crizanlizumab's MOA. "'Crizanlizumab acts by binding to P selectin...
...cell CLL lymphoma 11A HDAC - Histone deacetylase IL-1β - Interleukin-1 β SELP (CD62P) - P selectin Karen...
BioCentury | Oct 21, 2019
Emerging Company Profile

Verseau unveils tumor macrophage reprogramming strategy

...None issued Targets PD-1 (PDCD1; CD279) - Programmed cell death 1 PSGL-1 (CD162; SELPLG) - P selectin...
...Signal regulatory protein alpha STAB1 (CLEVER-1; FEEL-1) - Stabilin 1 Sandi Wong, Staff Writer Verseau Therapeutics Inc. P selectin...
Items per page:
1 - 10 of 251